Kallikreins as Prognostic Factors in Pancreatic Cancer
Author Information
Author(s): Rückert F, Hennig M, Petraki C D, Wehrum D, Distler M, Denz A, Schröder M, Dawelbait G, Kalthoff H, Saeger H-D, Diamandis E P, Pilarsky C, Grützmann R
Primary Institution: University Hospital Carl Gustav Carus, Technical University of Dresden
Hypothesis
The co-expression of KLK6 and KLK10 serves as a prognostic factor for survival in pancreatic ductal adenocarcinoma (PDAC).
Conclusion
Co-expression of KLK10 and KLK6 is associated with worse survival outcomes in patients with PDAC.
Supporting Evidence
- KLK10 and KLK6 were found to be overexpressed in pancreatic cancer tissues compared to normal tissues.
- Patients with strong co-expression of KLK10 and KLK6 had a median survival time of 20 months, compared to 29 months for those with weak expression.
- Statistical analysis confirmed that co-expression of KLK10 and KLK6 is an independent prognostic factor for survival.
Takeaway
This study found that two proteins, KLK10 and KLK6, when found together in pancreatic cancer, can mean the cancer is more aggressive and harder to treat.
Methodology
The study used immunohistochemistry and ELISA to evaluate protein expression and serum levels of KLK6 and KLK10 in patient samples.
Limitations
The study did not assess the use of KLK6 and KLK10 as serum biomarkers in PDAC due to lack of significant differences in serum levels between patients and healthy donors.
Participant Demographics
Patients included 54 individuals with histologically confirmed PDAC, with no prior adjuvant chemotherapy.
Statistical Information
P-Value
P=0.031 for survival correlation, P=0.017 for R1-resection status, P=0.043 for co-expression as a prognostic factor.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website